Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06148038 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CBD for Breast Cancer Primary Tumors

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 years 5 months later Mar 25, 2028 → Aug 28, 2030
See other at-risk trials from Medical University of South Carolina

Record History

  1. Primary completion pushed from Mar 25, 2028 to Aug 28, 2030 Completion pushed from Mar 25, 2029 to Aug 28, 2031 · Start date changed from estimate of Sep 15, 2026 to Sep 18, 2026 · Eligibility criteria expanded, about 28 words Show 3 more changesShow less
    • Completion pushed from Mar 25, 2029 to Aug 28, 2031
    • Start date changed from estimate of Sep 15, 2026 to Sep 18, 2026
    • Eligibility criteria expanded, about 28 words
  2. Start date: Jun 15, 2026 to Sep 15, 2026v12
  3. Re-verified, no change to tracked fieldsv11
  4. Primary completion pushed from Jan 1, 2027 to Mar 25, 2028 Recruitment opened · Enrollment increased: 60 → 84 participants · Completion pushed from Jan 1, 2028 to Mar 25, 2029 · 1 morev10 Show 4 more changesShow less
    • Recruitment opened
    • Enrollment increased: 60 → 84 participants
    • Completion pushed from Jan 1, 2028 to Mar 25, 2029
    • Eligibility criteria shortened, about 4 words

    See this version in full on ClinicalTrials.gov ↗

  5. Trial status: Not Yet Recruiting to Recruiting Primary completion date: Jan 1, 2027 to Mar 25, 2028 · Study sites: 0 to 1 · Completion date: Jan 1, 2028 to Mar 25, 2029v9 Show 3 more changesShow less
    • Primary completion date: Jan 1, 2027 to Mar 25, 2028
    • Study sites: 0 to 1
    • Completion date: Jan 1, 2028 to Mar 25, 2029
Show 7 earlier versionsHide 7 earlier versions
  1. Start date: Mar 15, 2026 to Jun 15, 2026v8
  2. Start date: Mar 1, 2026 to Mar 15, 2026v7
  3. Start date: Sep 30, 2024 to Mar 1, 2026 Primary completion date: Sep 30, 2026 to Jan 1, 2027 · Completion date: Sep 30, 2027 to Jan 1, 2028v6 Show 2 more changesShow less
    • Primary completion date: Sep 30, 2026 to Jan 1, 2027
    • Completion date: Sep 30, 2027 to Jan 1, 2028
  4. Primary completion date: Sep 30, 2025 to Sep 30, 2026 Start date: May 31, 2024 to Sep 30, 2024 · Completion date: Sep 30, 2026 to Sep 30, 2027v5 Show 2 more changesShow less
    • Start date: May 31, 2024 to Sep 30, 2024
    • Completion date: Sep 30, 2026 to Sep 30, 2027
  5. Start date: Jan 31, 2024 to May 31, 2024v4
  6. Start date: Nov 30, 2023 to Jan 31, 2024v3
  7. Study title shortened, about 7 wordsv2 See this version in full on ClinicalTrials.gov ↗
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a randomized placebo controlled partially blinded window of opportunity trial. A maximum of 84 patients with invasive breast cancer will be enrolled. Patients will be randomized 2:2:1:1 to either CBD low dose, CBD high dose, matching low dose placebo, or matching high dose placebo using permuted block randomization with random block sizes of 6 or 12. The time window between CBD or placebo initiation and surgery will be between 5 and 56 days.
Trial Details
NCT Number NCT06148038
Lead Sponsor Medical University of South Carolina
Conditions Breast Cancer
Enrollment 84 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov